Cramer continued to search for the hottest biotech companies of the year with his series on the next generation of biotech.
Esperion Therapeutics was on fire in 2014, rallying 209 percent. It focuses on finding treatments for high LDL cholesterol and other cardio-metabolic risk factors. Its massive run has been related to its drug that lowers LDL cholesterol for patients who are unable to tolerate traditional statins.
To find out if this stock can keep running in 2015 Cramer spoke with Tim Mayleban, CEO of Esperion. He estimated that there are approximately 7 million to 8 million patients who suffer from muscle pain and weakness from side effects associated with taking statins.
"We expect to start our Phase 3 program later this year. We are still a few years out, but we have made huge progress over the last several years," said Mayleban.
One of the companies that is on the forefront of making the next generation of biotech possible is Charles River Laboratories. This company is a contract research organization that provides biopharma businesses with what they need to discover new drugs and conduct clinical trials.
Cramer has been a fan of Charles River because as the trend of outsourcing increases in the biotech and pharma industry, Charles River is at the center of it all.
Charles River CEO Jim Foster spoke with Cramer on the impact that the next generation tech companies are having, citing an increase in clients stemming from the use of technology.
"Virtual companies and companies that have technology platforms want to use outside providers and partners like Charles River to try to accelerate the process and get the drugs to market. We are enjoying our collaboration with these companies, both large and small," said Foster.
In the Lightning Round, Cramer gave his take on a few caller favorites:
Teekay Corp: "I say keep looking. I don't want you in oil companies, but if you are going to be in that area, at least be in the best of breed. That is Nordic American Breed, that has a big dividend boost...I don't like the group, but this is the one to be in."
STMicroelectronics: "No, you want to be in NXP Semiconductors. But that one is really, really high. It is a better company. I have been telling people for lower risk to buy Cypress Semiconductor because of the merger and because of the yield."
PepsiCo: "I happen to be a big Indra Nooyi fan, and believe that PepsiCo represents good value here and great value at $90."
Read MoreLightning Round: The greatest growth companies of all-time